

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 January 2022 (20.01.2022)



(10) International Publication Number
WO 2022/012680 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C12N 15/62 (2006.01)
C07K 16/46 (2006.01) A61K 39/395 (2006.01)
C12N 5/10 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CN2021/106886

(22) International Filing Date:

16 July 2021 (16.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/102463

16 July 2020 (16.07.2020)

CN

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: NANJING LEGEND BIOTECH CO., LTD.

[CN/CN]; No. 6 Building Of Nanjing Life Science Town,
No. 568 Longmian Avenue, Jiangning District, Nanjing,
Jiangsu 211100 (CN).

(72) Inventors: FAN, Xiaohu; 1067 Armitage Crescent SW,

Edmonton, Alberta T6W 0K3 (CA). ZHOU, Zhe; 4th
Floor, Building A, Tsinghua Tongfang Industrial Park,
No.33 Jingyou Road, Jiangning District, Nanjing, Jiang-
su 211100 (CN). ZHUANG, Qiuchuan; Room 104, 36th
Building, Yuecheng International Garden, No.9, Huashen
Street, Yuhuatai District, Nanjing, Jiangsu 210012 (CN).
FANG, Xu; Room 1502, 5th Building, Zhongliangxi-
angyun, No.28, Pengshan Street, Jiangning District, Nan-
jing, Jiangsu 211100 (CN). PAN, Hongbo; 4th Floor,
Building A, Tsinghua Tongfang Industrial Park, No.33
Jingyou Road, Jiangning District, Nanjing, Jiangsu 211100
(CN). WEI, Min; No.6 Building Of Nanjing Life Science
Town, No. 568 Longmian Avenue, Jiangning District, Nan-
jing, Jiangsu 211100 (CN). ZHU, Jianrui; No.6 Building
Of Nanjing Life Science Town, No. 568 Longmian Avenue,
Jiangning District, Nanjing, Jiangsu 211100 (CN).

(74) Agent: AFD CHINA INTELLECTUAL PROPERTY

LAW OFFICE; Tower B, 21st Fl., Suite 2108, 38 Xueqing
Road, Haidian, Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: CD20 BINDING MOLECULES AND USES THEREOF

(57) Abstract: The present disclosure provides single domain antibodies that bind to CD20, and chimeric antigen receptors comprising same. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.

WO 2022/012680 A1